Clinical trial Recruiting at 1 site Interventional Women only

Moderate-intensity aerobic and resistance exercise to reduce pain sensitization in breast cancer survivors

Official title: Moderate-Intensity Exercise and Pain Sensitization in Breast Cancer Survivors: A Case-Based Study

Run by Universidad Rey Juan Carlos · NCT07128030 · Data updated 2026-11-12

This program will try a supervised moderate-intensity aerobic plus resistance exercise regimen to see if it reduces pain sensitization and persistent upper-limb pain in breast cancer survivors.

Quick facts

Study typeInterventional
SexWomen only
Enrollment10 (estimated)
SponsorUniversidad Rey Juan Carlos
Academic / other
Drugs / interventionschemotherapy
Locations1 site (Madrid)
StatusRecruiting
StartedAugust 23, 2025
Main results expectedFebruary 23, 2026
Study endsFebruary 23, 2026
Registry record updatedNovember 24, 2025
Trial IDNCT07128030 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adult women with stage I–III breast cancer who finished active treatment at least six months ago, have persistent upper-limb pain or altered sensation related to treatment, can perform moderate-intensity exercise, and can attend sessions in Madrid (Spanish speakers).

Probably not a fit

People unlikely to benefit include those with bilateral breast cancer, locoregional recurrence, other active malignancies, pre-existing non–treatment-related pain, neurological or cognitive disorders, contraindications to moderate exercise, or who cannot attend sessions or speak Spanish.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a supervised, combined moderate-intensity aerobic and resistance training program aimed at reducing pain sensitization in women who completed treatment for stage I–III breast cancer at least six months earlier and who report persistent upper-quadrant pain. The primary goals are to test feasibility, safety, and acceptability of the exercise intervention. Secondary measures include changes in pain intensity, somatosensory sensitivity, and temporal summation using quantitative sensory testing, while tertiary outcomes track quality of life and functional capacity. The intervention is delivered at Universidad Rey Juan Carlos with clinical collaboration from Hospital General Universitario Gregorio Marañón in Madrid.

Why it matters

Potential benefit: If successful, the program could lower pain sensitization and chronic pain intensity, improving function and quality of life for breast cancer survivors.

How similar studies have gone: Previous exercise programs have shown improvements in pain, function, and quality of life for breast cancer survivors, but targeted interventions specifically focused on reducing pain sensitization and temporal summation are less well established.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Adult women diagnosed with stage I-III breast cancer
* Completion of active treatment (surgery, chemotherapy, and/or radiotherapy) at least 6 months prior to enrollment
* Presence of persistent pain or altered sensation in the upper quadrant of the affected limb related to oncologic treatment

Exclusion Criteria:

* Bilateral breast cancer
* Locoregional recurrence
* Other malignancies
* Pre-existing pain not related to cancer treatment
* Neurological or cognitive disorders
* Non-Spanish speakers
* Contraindications to moderate-intensity physical activity

Where it's running

  • Universidad Rey Juan Carlos
    Madrid, Spain
    Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.